144 related articles for article (PubMed ID: 19835466)
1. Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan.
Locatelli F; Palmer BF; Kashihara N; Ecder T
Curr Med Res Opin; 2009 Dec; 25(12):2933-49. PubMed ID: 19835466
[TBL] [Abstract][Full Text] [Related]
2. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
[TBL] [Abstract][Full Text] [Related]
3. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.
Chrysant SG
Drugs Today (Barc); 2010 Mar; 46(3):151-62. PubMed ID: 20467589
[TBL] [Abstract][Full Text] [Related]
4. Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases.
Yarows SA
Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):19-33. PubMed ID: 20030022
[TBL] [Abstract][Full Text] [Related]
5. Aliskiren and valsartan combination therapy for the management of hypertension.
Epstein BJ
Vasc Health Risk Manag; 2010 Sep; 6():711-22. PubMed ID: 20859542
[TBL] [Abstract][Full Text] [Related]
6. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
Ferri C; Croce G; Desideri G
Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
[TBL] [Abstract][Full Text] [Related]
7. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
8. Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
Martin J; Krum H
Pharmacol Res; 2002 Sep; 46(3):203-12. PubMed ID: 12220962
[TBL] [Abstract][Full Text] [Related]
9. Valsartan in chronic heart failure.
Ripley TL
Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
[TBL] [Abstract][Full Text] [Related]
10. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
Ohishi M; Takeya Y; Tatara Y; Yamamoto K; Onishi M; Maekawa Y; Kamide K; Rakugi H
Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
[TBL] [Abstract][Full Text] [Related]
11. Valsartan and the kidney: review of preclinical and clinical data.
Ruilope LM
Adv Ther; 2001; 18(2):57-66. PubMed ID: 11446269
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
13. [Correction of aldosterone level as marker of RAAS dysfunction in patients with arterial hypertension degree II-III and chronic kidney diseases].
Dralova OV; Maksimov ML; Derbentseva EA; Ermolaeva AS; Starodubtsev AK
Eksp Klin Farmakol; 2011; 74(4):14-7. PubMed ID: 21678653
[TBL] [Abstract][Full Text] [Related]
14. Valsartan after myocardial infarction.
Güleç S
Anadolu Kardiyol Derg; 2014 Dec; 14 Suppl 2():S9-13. PubMed ID: 25604205
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease.
Hershon KS
Endocr Pract; 2011; 17(3):430-40. PubMed ID: 21454245
[TBL] [Abstract][Full Text] [Related]
16. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
17. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
Burchill LJ; Velkoska E; Dean RG; Griggs K; Patel SK; Burrell LM
Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
20. [Angiotensin II receptor blockers: current status and future prospects].
Corvol P; Plouin PF
Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
